Medscape6d
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
Prostate cancer drug now available to more patients with aggressive form of disease
Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...
Novartis After Sandoz: The Business Without Generics
Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...
NOLA.com3d
New prostate cancer drug can extend life expectancy by 8 months, Baton Rouge doctor says
"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...
PMLive5d
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
The Pharma Letter6d
Novartis’ Pluvicto gets FDA green light for mCRPC
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
Explore more
Cancer Therapy Advisor6d
FDA Expands Approval of Pluvicto in PSMA-Positive mCRPC
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
MPR4d
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
Localsyr.com on MSN3d
CNY man is first patient in US to receive new prostate cancer treatment in pre-chemotherapy setting
On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer pre-chemotherapy. Just six days ...
Pharmabiz6d
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...